Cost-effectiveness analysis of extended thromboprophylaxis with rivaroxaban versus no prophylaxis in high-risk patients after hospitalisation for COVID-19: an economic modelling study

https://www.thelancet.com/journals/lanam/article/PIIS2667-193X(23)00117-5/fulltext?dgcid=hubspot_email_covidalerts&utm_campaign=covidalerts&utm_medium=email&_hsmi=268172138&_hsenc=p2ANqtz-86euarvYtIFFCD3Brk7FLLZgP9OwJJ4tVBWsjFatCpGmHceyDAkyf_ePiGxQVHDlD6BX3Jn82G6W2ksrdQfP83KAuoTA&utm_content=268146206&utm_source=hs_email